On July 2, 2025, Barclays analyst Andrew Mok initiated coverage on Oscar Health (OSCR, Financial) with an 'Underweight' rating. The analyst set a price target of $17.00 USD for the stock.
This initiation by Barclays provides the first coverage update for Oscar Health (OSCR, Financial) by the firm, indicating a cautious outlook based on their analysis.
Investors and market participants will be watching closely how Oscar Health (OSCR, Financial) responds to this coverage as it could impact stock performance going forward.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 8 analysts, the average target price for Oscar Health Inc (OSCR, Financial) is $15.43 with a high estimate of $21.00 and a low estimate of $8.00. The average target implies an downside of 24.54% from the current price of $20.45. More detailed estimate data can be found on the Oscar Health Inc (OSCR) Forecast page.
Based on the consensus recommendation from 10 brokerage firms, Oscar Health Inc's (OSCR, Financial) average brokerage recommendation is currently 2.7, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Oscar Health Inc (OSCR, Financial) in one year is $14.67, suggesting a downside of 28.26% from the current price of $20.45. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Oscar Health Inc (OSCR) Summary page.
